Beau Noafshar, Fitch Solutions

Beau Noafshar, Fitch Solutions

1211_EDT_615

12 November 2020
In The Spotlight: How far are we in the vaccine race?
Markets and consumers were cheered as Pfizer reported that ithe Covid-19 vaccine candidate its is developing in partnership with BioNTech has an efficacy rate of above 90%. But what do we know about the vaccine? And what does this mean for the vaccine race? Prime Time's Rachel Kelly spoke to Beau Noafshar, Senior Pharmaceuticals & Healthcare Analyst, Fitch Solutions to find out.

Download the podcast.

Listen to his previous podcasts:

14 August 2020
In the Spotlight: What's next for a COVID-19 vaccine?
Russia recently announced that it has a vaccine ready and that it plans to start mass vaccinations as soon as October.
Despite this news, Fitch Solutions expects forecasts that a ciould be approved before or during the first half of 2021 based on the positive results in early-stage trials so far.
To find out more we spoke to Beau Noafshar, Senior Pharmaceuticals & Healthcare Analyst, Fitch Solutions.

Download the podcast.

Listen
Download SPH RADIO APP
Last Played
Last Played